恩替卡韦联合易善复治疗慢性乙型肝炎合并非酒精性脂肪肝疗效分析

Efficacy Analysis of Entecavir Combined with Yishanfu in the Treatment of Chronic Hepatitis B with Non-alcoholic Fatty Liver

目的探讨慢性乙型肝炎合并非酒精性脂肪肝治疗中恩替卡韦联合易善复的疗效。方法便利选择该院2016月1月—2019年1月收治的80例慢性乙型肝炎合并非酒精性脂肪肝患者,依据系统抽样法随机分组,40例对照组患者使用恩替卡韦治疗,40例观察组患者再联合使用易善复,对比两组肝功能指标、血脂水平、HBV-DNA载量和临床治疗效果。结果治疗后,观察组肝功能指标ALT(42.47±4.81)U/L高于对照组(35.36±4.52)U/L,AST(45.15±5.23)U/L、ALB(47.32±4.79)U/L、TBIL(11.63±1.74)μmol/L低于对照组(72.44±7.08)U/L、(72.58±7.83)U/L、(15.74±1.96)μmol/L,血脂指标HDL-C(1.86±0.29)mmol/L高于对照组(1.41±0.25)mmol/L,LDL-C(1.45±0.14)mmol/L、TC(2.35±0.36)mmol/L、TG(1.61±0.22)mmol/L低于对照组(2.23±0.26)、(3.08±0.45)、(1.96±0.24)mmol/L,观察组HBV-DNA载量(6.28±1.26)×10^2,低于对照组的(9.73±1.18)×10^2,差异有统计学意义(P<0.05);观察组临床有效率为95.00%,高于对照组的77.50%,差异有统计学意义(χ^2=5.165,P<0.05)。结论慢性乙型肝炎合并非酒精性脂肪肝治疗中联合应用恩替卡韦和易善复,抗病毒效果确切,还能减少肝脏脂类蓄积,促进脂肪肝恢复。

Objective To explore the efficacy of entecavir combined with Yishanfu in the treatment of chronic hepatitis B combined with non-alcoholic fatty liver.Methods The 80 subjects of this study were patients with chronic hepatitis B combined with non-alcoholic fatty liver who were admitted to the hospital from January 2016 to January 2019.They were convenienty selected and randomly grouped according to the systematic sampling method.40 control patients were treated with entecavir,40 patients in the observation group were combined with Yishanfu to The liver function indexes,blood lipid levels,HBV-DNA load and clinical treatment effects were compared between the two groups.Results After treatment,the liver function index ALT(42.47±4.81)U/L of the observation group was higher than that of the control group(35.36±4.52)U/L,AST(45.15±5.23)U/L,ALB(47.32±4.79)U/L,TBIL(11.63±1.74)μmol/L is lower than the control group(72.44±7.08)U/L,(72.58±7.83)U/L,(15.74±1.96)μmol/L,blood lipid index HDL-C(1.86±0.29)mmol/L is higher than the control group(1.41±0.25)mmol/L,LDL-C(1.45±0.14)mmol/L,TC(2.35±0.36)mmol/L,TG(1.61±0.22)mmol/L are lower the control group(2.23±0.26)mmol/L,(3.08±0.45)mmol/L,(1.96±0.24)mmol/L,observation group HBV-DNA load(6.28±1.26)×10^2,lower than control group(9.73±1.18)×10^2,the difference was statistically significant(P<0.05).The clinical effective rate of the observation group was 95.00%,which was higher than 77.50%of the control group.The difference was statistically significant(χ^2=5.165,P<0.05).Conclusion The combined application of entecavir and Yishanfu in the treatment of chronic hepatitis B combined with non-alcoholic fatty liver has a definite antiviral effect,and can reduce liver lipid accumulation and promote fatty liver recovery.